This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SR 147778
Description: Surinabant is the backup compound to Acomplia (Rimonabant). Like Acomplia, surinabant antagonizes the cannabinoid CB1 receptors. The binding of endogenous ligands, such as anadamide, to cannabinoid CB1 receptors in the brain increases appetite and other cravings such as smoking.
Additional information available to subscribers only: